Liverpool HIV Interactions

Concentrations of rosuvastatin are transiently increased when administered with elvitegravir and cobicistat. Dose modifications are not necessary when rosuvastatin is administered in combination with Genvoya. Coadministration of rosuvastatin (10 mg single dose) and elvitegravir/cobicistat (150/150 mg once daily) had no effect on elvitegravir AUC, Cmin and Cmax. Rosuvastatin AUC and Cmax increased by 38% and 89%, respectively.

Genvoya Summary of Product Characteristics, Gilead Sciences International Ltd, November 2021.

Coadministration of rosuvastatin (10 mg single dose) and elvitegravir/cobicistat (150/150 mg once daily) decreased elvitegravir Cmax and Cmin by 6% and 2%, but increased AUC by 2% (n=10). Rosuvastatin Cmax and AUC increased by 89% and 38%, respectively.

Genvoya US Prescribing Information, Gilead Sciences Inc, September 2021.

Coadministration of rosuvastatin (10 mg, single dose) with elvitegravir/cobicistat (150/150 mg) was studied in 10 healthy subjects in a crossover study. There was no significant effect on the pharmacokinetics of elvitegravir (2% increase in AUC, 6% decrease in Cmax) or cobicistat (no change in AUC or Cmax). Rosuvastatin AUC and Cmax increased by 38% and 89%, respectively. The authors conclude the increase in rosuvastatin exposure is not clinically relevant and no dose modification is required.

Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. Custodio J, Wang H, Hao J et al. J Clin Pharmacol, 2014, 54(6): 649-56.